Lexaria Bioscience Corp. (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, was featured in the latest episode of the “Stock2Me Podcast,” an IBN (InvestorBrandNetwork) solution to provide specialized content distribution via widespread syndication channels. Lexaria’s CEO and Chairman Chris Bunka joined the latest episode to discuss the company’s business model, his professional background and the team behind Lexaria, as well as the company’s recent transformative steps to position it for accelerated growth. “Our company kind of had a rebirth in January 2021. … We completed a 1-for-30 reverse stock split,” Bunka explained. “That was really hard, and just so you all know, I was the biggest shareholder. I am still the biggest shareholder. I took a big hit on my own holdings, but we had to do that to make the company attractive for future shareholders. … We got listed on Nasdaq in January and completed an $11 million financing. That was the biggest financing in the history of the company, and it transformed us. … We were able to step on the gas pedal and basically work on our research and development and our commercial studies at a 5-10x higher pace than anything we could do in the past. Therefore, this year, we’ve done more work than we did in the five years previous — all put together.”
To view the full press release, visit https://cnw.fm/eHvT6
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp.’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by up to 5-10x, reduce time of onset from 1-2 hours to minutes and mask unwanted tastes; it is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”) and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 21 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Do you have questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire is part of the InvestorBrandNetwork.